Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

Video

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

Scott T. Tagawa, MD, MS, FACP, professor of medicine and urology, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, attending physician, New York Presbyterian Hospital, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial (NCT04886986).

In the initial dose-escalation phase 1 trial, patients are receiving a fixed dose of 6.8 GBq intravenous (IV) 177Lu-PSMA-I&T every 3 weeks plus escalating doses of IV 225Ac-J591 in different cohorts, between 30 and 40 KBq/kg, Tagawa explains. Specifically, the 2 cycles of 225Ac-J591 are given 8 weeks apart, Tagawa adds.

Although the phase 1 trial is ongoing, 225Ac-J591 has appeared to be tolerable in 9 patients in 2 cohorts, Tagawa continues. No dose-limiting toxicities (DLTs) were observed in the initial 3 patients treated in the low-dose 225Ac-J591 cohort, Tagawa says. There have been no clear DLTs in the second cohort in ongoing follow-up. However, in early follow-up, 1 patient presented with grade 3 thrombocytopenia, Tagawa concludes.

Related Videos
Robert Huddart, PhD, leader, Clinical Academic Radiotherapy Team, The Institute of Cancer Research; professor, urological cancer, honorary consultant, Urological Oncology, The Royal Marsden NHS Foundation Trust
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine